Israel · Delayed Price · Currency is ILS · Price in ILA Evogene Statistics
Total Valuation
Evogene has a market cap or net worth of ILS 19.51 million. The enterprise value is 25.01 million.
| Market Cap | 19.51M |
| Enterprise Value | 25.01M |
Important Dates
The next estimated earnings date is Thursday, November 19, 2026.
| Earnings Date | Nov 19, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Evogene has 15.80 million shares outstanding. The number of shares has increased by 51.18% in one year.
| Current Share Class | 15.80M |
| Shares Outstanding | 15.80M |
| Shares Change (YoY) | +51.18% |
| Shares Change (QoQ) | +25.28% |
| Owned by Insiders (%) | 8.51% |
| Owned by Institutions (%) | 5.63% |
| Float | 14.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.95 |
| PB Ratio | 1.14 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.07 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.57, with a Debt / Equity ratio of 0.36.
| Current Ratio | 3.57 |
| Quick Ratio | 3.23 |
| Debt / Equity | 0.36 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.19 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -182.75% and return on invested capital (ROIC) is -77.61%.
| Return on Equity (ROE) | -182.75% |
| Return on Assets (ROA) | -37.53% |
| Return on Invested Capital (ROIC) | -77.61% |
| Return on Capital Employed (ROCE) | -136.78% |
| Weighted Average Cost of Capital (WACC) | 6.13% |
| Revenue Per Employee | 94,930 |
| Profits Per Employee | -519,796 |
| Employee Count | 52 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 2.71 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -68.50% in the last 52 weeks. The beta is 0.70, so Evogene's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | -68.50% |
| 50-Day Moving Average | 165.68 |
| 200-Day Moving Average | 232.28 |
| Relative Strength Index (RSI) | 35.82 |
| Average Volume (20 Days) | 109,412 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Evogene had revenue of ILS 4.94 million and -27.03 million in losses. Loss per share was -2.68.
| Revenue | 4.94M |
| Gross Profit | -3.34M |
| Operating Income | -42.36M |
| Pretax Income | -49.39M |
| Net Income | -27.03M |
| EBITDA | -41.32M |
| EBIT | -42.36M |
| Loss Per Share | -2.68 |
Balance Sheet
The company has 27.75 million in cash and 6.26 million in debt, with a net cash position of 21.49 million or 1.36 per share.
| Cash & Cash Equivalents | 27.75M |
| Total Debt | 6.26M |
| Net Cash | 21.49M |
| Net Cash Per Share | 1.36 |
| Equity (Book Value) | 17.18M |
| Book Value Per Share | -0.72 |
| Working Capital | 23.27M |
Cash Flow
In the last 12 months, operating cash flow was -32.61 million and capital expenditures -71,498, giving a free cash flow of -32.68 million.
| Operating Cash Flow | -32.61M |
| Capital Expenditures | -71,498 |
| Depreciation & Amortization | 1.07M |
| Net Borrowing | -1.56M |
| Free Cash Flow | -32.68M |
| FCF Per Share | -2.07 |
Margins
| Gross Margin | -67.59% |
| Operating Margin | -858.18% |
| Pretax Margin | -1,000.48% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Evogene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -51.18% |
| Shareholder Yield | -51.18% |
| Earnings Yield | -138.51% |
| FCF Yield | -167.48% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 28, 2024. It was a reverse split with a ratio of 0.1.
| Last Split Date | Jul 28, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Evogene has an Altman Z-Score of -32.17 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -32.17 |
| Piotroski F-Score | 1 |